Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • CMS proposes Medicare reimbursement — AOTI benefits from topical wound oxygen therapy

    The US agency CMS has published a draft that would deem topical oxygen therapy medically necessary for diabetic foot ulcers after four weeks of non‑healing and provide for nationwide Medicare reimbursement. The draft enters a 45‑day comment period; a final decision is expected within a year. AOTI reports a 75% market share in this segment, expects an addressable market potential of up to $26 billion with reimbursement, and cites a near‑term revenue potential of around $400 million with existing payer coverage. » More on de.investing.com

Financials

In the last quarter, AOTI INC had revenue of €29.06M and net profit of €2.03M
(EUR) December 2025
YoY
Revenue 29.06M -
Gross profit 16.23M -
Net profit 2.03M -
EBITDA 3.81M -

Fundamentals

Metric Value
Market capitalization
€178.82M
Number of shares
106.36M
52-week high/low
€1.80 - €0.30
Dividends No
Beta
2.88
P/E ratio
74.28
PEG ratio
0.74
P/B ratio
9.40
P/S ratio
2.90

Company profile

Name
AOTI INC
CEO
Michael Griffiths
Employees 90

Ticker symbols

Exchange Symbol
London
AOTI.L
🍪

Parqet  uses cookies. Learn more